High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses

Pathology International

Volumn 65, Issue 10, 2015, Pages 528-535

  Oishi, Naoki ^a   Kondo, Tetsuo ^a   Nakazawa, Tadao ^a   Mochizuki, Kunio ^a   Tanioka, Fumihiko ^b   Oyama, Toshio ^c   Yamamoto, Tomoko ^d   Iizuka, Junpei ^d   Tanabe, Kazunari ^d   Shibata, Noriyuki ^d   Kirito, Keita ^a   Katoh, Ryohei ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Iwata City Hospital   (Japan)

^c Yamanashi Prefectural Central Hospital   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Diffuse large B cell lymphoma; Gene amplification; Immunohistochemistry; Mutation; MYD88; Testis

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MYELOID DIFFERENTIATION FACTOR 88 GENE; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TESTIS TUMOR; VERY ELDERLY; B LYMPHOCYTE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; PATHOLOGY; PROCEDURES; TESTICULAR NEOPLASMS;

MYD88 PROTEIN, HUMAN; MYELOID DIFFERENTIATION FACTOR 88;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; PREVALENCE; TESTICULAR NEOPLASMS;

EID: 84942593848     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12336     Document Type: Article

References (27)

1. Ahmad SS, Idris SF, Follows GA, Williams MV. Primary testicular lymphoma. Clin Oncol (R Coll Radiol) 2012; 24: 358-365.
2. Horne MJ, Adeniran AJ. Primary diffuse large B-cell lymphoma of the testis. Arch Pathol Lab Med 2011; 135: 1363-1367.
3. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362: 1417-1429.
4. Hans CP, Weisenburger DD, Greiner TC etal. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
5. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003; 100: 9991-9996.
6. Fonseca R, Habermann TM, Colgan JP etal. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000; 88: 154-161.
7. Li D, Xie P, Mi C. Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype. Pathol Res Pract 2010; 206: 611-615.
8. Zucca E, Conconi A, Mughal TI etal. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20-27.
9. Al-Abbadi MA, Hattab EM, Tarawneh MS, Amr SS, Orazi A, Ulbright TM. Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: A study of 18 cases. Mod Pathol 2006; 19: 1521-1527.
10. Booman M, Douwes J, Glas AM, de Jong D, Schuuring E, Kluin PM. Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. J Pathol 2006; 210: 163-171.
11. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 2010; 11: 373-384.
12. Lohr JG, Stojanov P, Lawrence MS etal. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012; 109: 3879-3884.
13. Ngo VN, Young RM, Schmitz R etal. Oncogenically active MYD88 mutations in human lymphoma. Nature 2010; 470: 115-119.
14. Xu L, Hunter ZR, Yang G etal. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013; 121: 2051-2058.
15. Gonzalez-Aguilar A, Idbaih A, Boisselier B etal. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012; 18: 5203-5211.
16. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 2011; 122: 791-792.
17. Pham-Ledard A, Prochazkova-Carlotti M, Andrique L etal. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol 2014; 27: 402-411.
18. Kraan W, Horlings HM, van Keimpema M etal. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 2013; 3: e139.
19. Kraan W, van Keimpema M, Horlings HM etal. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 2014; 28: 719-720.
20. Zucca E. Extranodal lymphoma: A reappraisal. Ann Oncol 2008; 19 (Suppl 4): iv77-80.
21. Swerdlow SH. WHO Classification of Tumours of Haematopoitetic and Lymphoid Tissues. Lyon: IARC PRESS, 2008.
22. Choi JW, Kim Y, Lee JH, Kim YS. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 2013; 44: 1375-1381.
23. Pelletier RM. The blood-testis barrier: The junctional permeability, the proteins and the lipids. Prog Histochem Cytochem 2011; 46: 49-127.
24. Bhagavathi S, Sharathkumar A, Hunter S etal. Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas. Clin Neuropathol 2008; 27: 13-20.
25. Camilleri-Broet S, Criniere E, Broet P etal. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: Analysis of 83 cases. Blood 2006; 107: 190-196.
26. Schlegel U, Schmidt-Wolf IG, Deckert M. Primary CNS lymphoma: Clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000; 181: 1-12.
27. Yang Y, Shaffer AL 3rd, Emre NC etal. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723-737.